drugset / Trial / NCT00500058
A Phase I, Dose-Escalation Study to Assess the Safety and Biological Activity of Recombinant Human Interleukin-18
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose is to identify a dose of SB-485232 which is safe, tolerable and effective when used in combination with Rituximab in patients with non-Hodgkin's lymphoma (NHL). This study will use a standard treatment regimen of Rituximab in combination with rising doses of SB-485232. The dose selected from this study will be used in a future studies.
Timeline
- Start
- 2007-07-31
- Primary completion
- 2010-03-04
- Completion
- 2010-03-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | IBOCTADEKIN | Protein / enzyme biologic | 1 ug/kg | Intravenous |
| Subject | IBOCTADEKIN | Protein / enzyme biologic | 100 ug/kg | Intravenous |
| Background | Rituximab | Monoclonal antibody | 375 mg/m2 | Intravenous |